6. Summary
According to above compelling evidences, we speculated that consumption of ACE2 would enhance the ACE/Ang Ⅱ/AT1R axis but inhibit the ACE2/Ang (1-7)/MasR axis, which resulted in imbalance of RAAS, and thus increased the inflammatory response. Rebalancing the RAAS may be the therapeutic and preventive strategy for COVID-19 patients. Interventions for rebalancing the RAAS include the treatment of rhACE2, ACEI/ARB, Ang (1-7), alamandine and so on. These interventions may upregulate ACE2 expression, while there is no evidence to support the possibility of increasing the susceptibility of SARS-CoV-2. Nevertheless, the experimental findings have demonstrated that upregulating ACE2 may shift the balance of RAAS axes from ACE/Ang Ⅱ/AT1R axis to the ACE2/Ang (1-7)/Mas axis. Meanwhile, lots of clinical trials have demonstrated rebalancing the RAAS does play a protective role in improvement of inflammation. Therefore, we discuss our current understanding about the role of ACE2 in organs injury secondary to the COVID-19, explore the benefit effects of the ACE2/Ang (1-7)/Mas axis, and then make our point that rebalances the RAAS can be the therapeutic and preventive strategy. However, further investigation is required to demonstrate whether these experimental effects could be translated into clinical benefit.